About Us
A high-tech medical device company specializing in Brain-Computer Interfaces and intelligent neurorehabilitation, headquartered in Australia.
Who We Are
We are a high-tech medical device company specializing in Brain-Computer Interfaces (BCI) and intelligent neurorehabilitation. Leveraging Australia's premier biomedical research environment and relatively flexible regulatory pathways for innovative devices, we are dedicated to developing next-generation minimally invasive implantable and high-precision non-invasive neuromodulation devices.
We adopt a dual-track strategy of "R&D and Registration in Australia, serving the Asia-Pacific market," aiming to bridge the gap between China's high-end neuromodulation market and Australia's advanced medical technology.
Unlike competitors focused on single markets, we have pioneered a cross-border operational model of "Australian Technology + Chinese Intelligent Manufacturing + Global Market."
Vision & Mission
"Decoding the Neural Code, Restoring the Dignity of Life."
We are committed to breaking the physical confinement brought by neurodegenerative diseases and accidents through minimally invasive BCI technology, enabling every patient to regain the ability to communicate and live autonomously.
Technological Vision
Define the global standard for Endovascular Neuromodulation. Short-term (2028): establish NeuralStent™ as the third "organ" implanted via blood vessels. Long-term (2035): achieve bidirectional neural communication for both motor restoration and mental health.
Industrial Vision
Build a "Super Connector" for cross-border healthcare. Use Australian TGA certification as a quality endorsement, and China's efficient supply chain to reduce costs — making high-end neuromodulation accessible to all.
Social Vision
Eliminate social isolation caused by disability. ALS patients will use their thoughts to control smart homes and communicate freely. We will extend BCI from critical care to aging intervention, helping millions maintain cognitive function.
Our Cross-Border Strategy
Australian Benchmark
TGA certification as the global quality endorsement — "Australian R&D = Safe and Reliable."
China Speed
Greater Bay Area supply chain transforms expensive "aristocratic medicine" into affordable universal healthcare.
Global Market
Targeting Asia-Pacific first, then expanding globally with a proven dual-market validation model.